Scorpion Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in Boston, Massachusetts. Founded in 2020, it specializes in developing small-molecule targeted therapies for cancer patients, leveraging advanced technologies in cancer biology, medicinal chemistry, chemical proteomics, structure-based drug design, and data sciences including machine learning.
The company focuses on creating highly selective inhibitors against validated but challenging cancer targets, such as mutant-selective PI3Kα (STX-478, acquired by Eli Lilly), next-generation EGFR inhibitors (partnered with Pierre Fabre), and other programs addressing undruggable targets through collaborations like the one with AstraZeneca on transcription factors.
Scorpion's pipeline has included three clinical-stage candidates and multiple preclinical programs. Parts of its assets have been divested, including a spin-out to Antares Therapeutics in 2025 for further development in oncology and other diseases. With around 140 employees at its peak, Scorpion aims to expand precision medicine to broader cancer patient populations.
